These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9232443)

  • 21. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: association with interleukin-1 production.
    Itoh K; Balch CM; Trial J; Platsoucas CD
    Cell Immunol; 1988 Jul; 114(2):257-71. PubMed ID: 3260540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
    Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322.
    Nizet Y; Chentoufi AA; de la Parra B; Lewalle P; Rouas R; Cornet A; Besse T; Mourad M; Malaise J; Squifflet JP; Bazin H; Latinne D
    Transplantation; 2000 Apr; 69(7):1420-8. PubMed ID: 10798765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.
    Caillat-Zucman S; Blumenfeld N; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplantation; 1990 Jan; 49(1):156-60. PubMed ID: 2137271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
    Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
    Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
    Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
    Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-OKT3 induction therapy CD complex response predicts renal allograft rejection.
    Stephan RN; Munschauer CE; Kohli RK; Sridhar NR; Hoover EL; Davidson IJ
    Transplantation; 1997 Apr; 63(8):1183-6. PubMed ID: 9133483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
    Popma SH; Griswold DE; Li L
    Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
    Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
    Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
    Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
    J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation.
    Swinnen LJ; Fisher RI
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):670-8. PubMed ID: 7859029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic monitoring during OKT3 therapy.
    Chatenoud L
    Clin Transplant; 1993 Aug; 7(4 Pt 2):422-30. PubMed ID: 10146352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.